Unlocking the Potential of CYP11A1 as a Drug Target and Biomarker

Target Name: CYP11A1

NCBI ID: G1583

CYP11A1

Unlocking the Potential of CYP11A1 as a Drug Target and Biomarker

CYP11A1, a gene encoding the enzyme cholesterol 20-22 desmolase (CYP11A1), has been identified as a potential drug target and biomarker for various diseases, including cardiovascular diseases, metabolic disorders, and neurodegenerative diseases. CYP11A1 is a key enzyme involved in the synthesis and degradation of cholesterol, which is a crucial lipid molecule that plays a vital role in various physiological processes, including cell signaling, membrane structure, and hormone production. Malfunctioning CYP11A1 has been implicated in the development and progression of numerous diseases, including hyperlipidemia, stroke, and Alzheimer's disease. As such, targeting CYP11A1 has the potential to provide new therapeutic approaches for treating a range of disorders.

CYP11A1 Structure and Function

CYP11A1 is a member of the CYP enzyme family, which is responsible for the synthesis of a wide range of compounds, including drugs, toxins, and natural products. The CYP11A1 gene encodes a 164-amino acid protein that functions as the enzyme responsible for the synthesis of 20-hydroxycholesterol (C20H22) from its starting material, 22-hydroxycholesterol (C22H20).

CYP11A1 is a cytoplasmic protein that is primarily located in the endoplasmic reticulum (ER) and perinuclear matrix (PM) of cells. It is highly conserved across various species, with only minor differences in its catalytic mechanism and substrate specificity. CYP11A1 has a unique catalytic mechanism, as it uses a unique substrate-protein interaction to promote the synthesis of C20H22 from its starting material.

CYP11A1 has been shown to play a crucial role in the regulation of cellular cholesterol levels, as well as the synthesis and degradation of various metabolites. It is highly expressed in various tissues, including liver, muscle, and brain, and is also expressed in various cell types, including immune cells and cancer cells. CYP11A1 has also been shown to be involved in various cellular signaling pathways, including the regulation of cell growth, apoptosis, and inflammation.

CYP11A1 as a Drug Target

The potential of CYP11A1 as a drug target is based on its involvement in various cellular processes that are associated with the development and progression of diseases. Several studies have shown that CYP11A1 is involved in the regulation of cellular signaling pathways that are critical for the development of cancer, neurodegenerative diseases, and cardiovascular diseases. As such, targeting CYP11A1 has the potential to provide new therapeutic approaches for treating these disorders.

One of the key advantages of targeting CYP11A1 is its involvement in the regulation of cellular signaling pathways that are critical for the development and progression of cancer. CYP11A1 has been shown to be involved in the regulation of various cellular signaling pathways, including the TGF-β pathway, which is involved in the regulation of cell growth, apoptosis, and differentiation. Additionally, CYP11A1 has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and metabolism.

Targeting C

Protein Name: Cytochrome P450 Family 11 Subfamily A Member 1

Functions: A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones (PubMed:21636783). Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal (PubMed:21636783). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin) (PubMed:21636783)

The "CYP11A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP11A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets